Study Participants Wanted

Note: Only studies being conducted by the UMass Department of Psychiatry will be listed here. No other entries accepted.

Members of the department wishing to submit information like this should use the format below, include a subject line of “Study Participants Wanted,” and email it to psychiatrycommunications@umassmed.edu.


The Depression Relapse Trial

Individuals that are currently suffering from depression are invited to participate in a research study to determine the effectiveness and safety of vortioxetine in preventing relapse in depression for those subjects who respond to treatment with vortioxetine. Study participation will last up to 55 weeks and subjects will receive the study drug vortioxetine.

Participants must be:

  • 18 to 75 years of age
  • suffering from recurrent Major Depressive Disorder
  • experiencing current symptoms of depression
  • not be pregnant or have plans to become pregnant

Subjects will receive study drug and study-related care at no cost. Compensation provided.

Contact Michelangela Yusif @ 774-455-4136

Docket # H-00007086


Investigational Drug Study for Adolescents with Schizophrenia

What are we studying?
The purpose of the study is to evaluate whether NaBen (Sodium Benzoate) is an effective add-on treatment for adolescents with schizophrenia

Who can participate?
Adolescents between 12 and 17 years of age who have a diagnosis schizophrenia. Participants need to be on a stable antipsychotic treatment for their schizophrenia and still be experiencing residual symptoms.

How will participants be compensated?
Compensation will be provided for time and travel.

For more information, contact CANDI at (774) 455-4100

Docket # H00005591 


Transition-age Youth Psychotherapy Experiences (TYPE) Study
UMass Medical School Transitions RTC Research Study for Young Adults (Ages 18-25)

The UMass Transitions Research and Training Center (RTC) is currently recruiting for a research study to better understand the experiences of young adults who are participating in outpatient psychotherapy treatment.

We are seeking:
Young adults between the ages of 18-25 who have a self-identified mental health condition and who are beginning outpatient psychotherapy or have been involved in outpatient psychotherapy for less than one year.

Participation:

  • Two interviews scheduled two months apart. Interviews will last roughly 1 hour and will include a web survey and qualitative portion.
  • Interviews will take place over the phone, or at a location of convenience (for participants located within 30 miles of Worcester, MA).
  • Participants will receive a $25 gift card for each interview completed. Young adults will be compensated up to $50 for their involvement in this study.

Please email, call, text, or visit the TYPE study webpage to learn more about the study and have all your questions answered:

Emma Pici-D’Ottavio
Call or text:774-437-2124
Email: Emma.PiciDOttavio@UMassMed.edu
Study webpage: http://www.voices4hope.net/type-study.html

IRB# H00007759


Collecting Histories of Education and Employment During Recovery
UMass Medical School Transitions RTC Research Study for young adults (ages 25-30) and young parents (ages 22-30)

The UMass Transitions Research and Training Center (RTC) is currently recruiting for a research study to better understand the employment and education experiences of young adults.


We are seeking:
Young adults ages of 25-30 or young parents ages 22-30 who have a history of a mental health condition to participate in one-time, 1.5-hour interview at a location of their choice to learn about their school and work experiences. Participants will receive a $30 gift card for their time.

To learn more please call, text, email or visit the CHEER study’s webpage:
Laura Golden
Call or text: 774-502-7813
Email: Laura.Golden@UMassmed.edu
CHEER Study Webpage: http://www.voices4hope.net/cheer-study.html

IRB# H00008523


Outpatient Couple Therapy for Service Members and Veterans with Alcohol-Related Concerns

The Alcohol Behavioral Couple Therapy Military treatment research program is specifically designed to help service members or veterans and their partners to learn skills that will help to reduce drinking and to improve relationship functioning.

The program will include a thorough assessment, 15 weekly outpatient sessions with a spouse, partner or family member (free of charge), and a follow-up session.  Compensation will be provided for the intake and follow-up sessions.

Below are the major inclusion criteria:

  • Be a service member or veteran of the U.S. Military (all branches welcome including National Guard and Reserves)
  • Have a drinking habit you want to change
  • Be 18 or older
  • Have a significant other who can attend sessions with you (spouse, dating partner, family member)

For more information, please contact Rachel Rosen (508-856-8745) or Dr. Beth Epstein (732-995-7315).

IRB# H-3823


12-week CBT and Self-Regulation Psychotherapy Group Treatment for Co-morbid Pain and Opioid Abuse

The goal of this study is to help participants simultaneously develop better pain management skills and reduce drug abuse. Our intervention may help reduce drug use and improve pain management.

This is a 15 visit study and participants are compensated for three assessment visits after completing the study.

Below are the major inclusion criteria:

  • Be between 18 and 65 years old
  • Have a history of co-morbid opioid addiction and chronic pain
  • Be on ONE of the following for opioid maintenance:
    • Methadone
    • Buprenorphine (Suboxone)

For more information contact Dr. Amy Wachholtz (508-334-2164).

IRB# H-14337


The Early Treatment Study

The goal of this study is to compare the standard treatment for psychosis with a treatment version of the medication aripiprazole that is taken only once each month. Study participants at this study location will receive the care your center usually provides. Those who qualify will receive study-related medical exams, and lab tests at no charge. People in this study will be compensated for their time. In order to participate in the study, individuals must be evaluated by a study doctor and meet certain criteria including, but not limited to:

  • male or female aged 18-35
  • have a clinical diagnosis of psychosis and up to 5 years of antipsychotic medication exposure

For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

Funding Source: Vanguard Research Group

IRB Docket#H00007426


Tardive Dyskinesia Study

We invite those who are experiencing involuntary movements in their face or other parts of their body – and suffer from schizophrenia, schizoaffective disorder – to see if they may qualify for the Kinect 3 Study. The purpose of this clinical research study is to evaluate the effectiveness, safety, and tolerability of an investigational oral medication for tardive dyskinesia. Those who qualify will receive study medication, study-related medical exams, and lab tests at no charge. In order to participate in the study, individuals must be evaluated by a study doctor and meet certain criteria including, but not limited to:

  • male or female aged 18 to 85 years
  • have clinical diagnosis of schizophrenia or schizoaffective disorder
  • have a clinical diagnosis of Tardive Dyskinesia (TD)

For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

IRB Docket#H00006334


A Psychotic Disorders Program Research Study

Exenatide weekly injection as an adjunctive treatment in patients with schizophrenia

Have you been diagnosed with Schizophrenia or Schizoaffective disorder? Are you interested in helping us learn if a drug called Exenatide may improve your memory and thinking?

If so, you may be eligible to participate in a research study at UMass Medical School. Studies suggest that Exenatide (an FDA-approved drug) can reduce inflammation, which may protect the brain and improve memory and thinking in individuals with schizophrenia or schizoaffective disorder. Your participation in the study will last 24 weeks (6 months).

You will be compensated (paid) for your time. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

Funding Source: Stanley Medical Research Institute
IRB Docket# H00004119


A Research Study on Treatment of Marijuana Use and Schizophrenia

The UMass Psychotic Disorders Research Program is running a NIH-funded study on marijuana abuse and schizophrenia.

People who have schizophrenia often abuse marijuana. We are studying whether an FDA approved Clozapine can reduce marijuana use.

The study last about 14 weeks and involves:

  • Weekly meetings with the research staff
  • Answering questions about substance use and current symptoms
  • Half the people in the study will get a medicine called “clozapine” and the other half will get a medicine called “risperidone”.

People in the study will not know which type of pill they are getting.

We are looking for people who:

  • Have been told they have schizophrenia
  • Are willing to take medicine for schizophrenia
  • Use marijuana regularly
  • Are ages 18-55

People in the study will be compensated for their time. All information is kept private.
For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu

Docket # H-00001171


The Psychotic Disorders Program at UMass Medical School is happy to share with you a NIH-funded study entitled Salsalate as an Adjunctive Treatment in Patients with Schizophrenia.

This is an open-label 12-week pilot research study examining how salsalate, an anti-inflammatory drug affects positive and negative symptoms of schizophrenia, Hemoglobin A1c, fasting glucose, other metabolic issues and cognitive functioning when added to an antipsychotic medication. We are seeking your help to recruit eligible subjects.

Inclusion Criteria

  • M/F, Age 18-65 years
  • Diagnosis of schizophrenia or schizoaffective disorder
  • Currently on a stable dose of antipsychotic medication (for at least one month)

Exclusion Criteria

  • Current substance abuse
  • Significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary or thyroid diseases.
  • Currently on immunosuppressant medication including oral steroids. 
  • Use of anti-coagulants. 

Subjects will be compensated for their time.

For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.
Docket # H-14814


The UMass Psychotic Disorders Research Program is running an NIH-funded study to investigate whether the combination of risperidone and desipramine is effective in reducing alcohol consumption in individuals suffering from schizophrenia and ongoing alcohol drinking. Below are the major inclusion and exclusion criteria:

Inclusion criteria: Age 18-65; Suffers from schizophrenia or schizoaffective disorder; Meets diagnostic criteria for current alcohol abuse or dependence

Exclusion Criteria: Suffers from any substance abuse disorder other than caffeine, nicotine, and cannabinoid containing substances; Continues to use alcohol despite treatment with medications such as naltrexone, acamprosate, disulfiram, topiramate, etc.

For more information contact Dr. Xiaoduo Fan (508-856-3881), or Dr. Amy Harrington (508-860-1260).

Docket #H-14857


ADHD Study

Men aged 14 – 24.

Participants must be diagnosed with ADHD and be right-handed.

Participants will be asked to fill out surveys and undergo a non-invasive MRI scan. No medication is given for this study.

Compensation will be provided for time and travel.
Contact: 508-856-8185 or email CCNI.Research@umassmed.edu.

Docket H-14119


Center for Psychopharmacologic Research and Treatment (CPRT)

Hormones in Pregnancy and Brain Imaging in Postpartum Depression Research Study

This NIH-funded study will monitor for symptoms of depression and anxiety during late pregnancy (2 visits) and after giving birth (3 visits). We also monitor blood hormone levels (each visit) and in the postpartum, participants will have one brain MRI scan done. Total participation is about 4-7 hours.
Participants in this study:

  • are 18-40 years old and pregnant 
  • are either: healthy without mood symptoms OR have some symptoms of depression or anxiety/stress 
  • plan to give birth at UMass Memorial Medical Center 
  • are not taking an antidepressant or steroid medication 

Participants will receive financial compensation as well study-related evaluations at no cost. Participants who complete the MRI brain scan will also receive a picture of their brain MRI scan.

To learn more, please contact the study doctor, Kristina M. Deligiannidis, M.D. @ 508-856-5928.

Docket # H-00001214

▴ Back To Top
Section Menu To Top